Emergence of KPC-8-producing K. pneumoniae infection without prior exposure to ceftazidime/avibactam: the threat of de novo infections by ceftazidime/avibactam-resistant KPC variants
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01494-24 ↗Kurz gefasst
Fallbericht in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von María Alejandra Mateo-Vargas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Biomedicina, Biotecnología y Salud Pública, Universidad de Cádiz, Cadiz, Spain. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azabicyclo Compounds, Bacterial Proteins, beta-Lactamases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Menarini Group (Menarini Ricerche SpA), Instituto de Salud Carlos III, Centro de Investigación Biotecnológica en Red de Enfermedades Infecciosas (CIBERINFEC).
Abstract (Originalsprache)
De novo infections caused by ceftazidime/avibactam-resistant KPC variants are rarely reported. We characterize the evolution of a KPC-8-producing Klebsiella pneumoniae strain involved in a primary infection without previous ceftazidime/avibactam treatment. During a 15-month follow-up, changes in carbapenem susceptibility due to porin alterations were observed, remaining susceptible to meropenem/vaborbactam, imipenem/relebactam, and cefiderocol. High- and low-permeability recombinant Escherichia coli isolates analysis revealed that, unlike the widespread ceftazidime/avibactam-resistant variant KPC-31, KPC-8 confers ceftazidime/avibactam resistance without decreasing carbapenemase activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Biomedicina, Biotecnología y Salud Pública, Universidad de Cádiz, Cadiz, Spain.
- Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña (Spain), A Coruña, Spain.
- CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Instituto de Biomedicina de Sevilla IBIS, Seville, Spain.
- Departamento de Microbiología, Universidad de Sevilla, Seville, Spain.
- Servicio de Microbiología and Instituto de Innovación e Investigación Biomédica de Cádiz (INIBICA), Hospital Universitario Puerta del Mar, Cadiz, Spain.
ORCID-Profile: María Alejandra Mateo-Vargas, Lorena López-Cerero, Fátima Galán-Sánchez
Förderung
- Menarini Group (Menarini Ricerche SpA)
- Instituto de Salud Carlos III
- Centro de Investigación Biotecnológica en Red de Enfermedades Infecciosas (CIBERINFEC)
- Axencia Galega de Innovación
Zitieren
APA
Mateo-Vargas, M. A., Rodríguez-Pallares, S., Arca-Suárez, J., López-Cerero, L., Rodríguez-Iglesias, M., & Galán-Sánchez, F. (2025). Emergence of KPC-8-producing K. pneumoniae infection without prior exposure to ceftazidime/avibactam: the threat of de novo infections by ceftazidime/avibactam-resistant KPC variants. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01494-24
Vancouver
Mateo-Vargas MA, Rodríguez-Pallares S, Arca-Suárez J, López-Cerero L, Rodríguez-Iglesias M, Galán-Sánchez F. Emergence of KPC-8-producing K. pneumoniae infection without prior exposure to ceftazidime/avibactam: the threat of de novo infections by ceftazidime/avibactam-resistant KPC variants. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01494-24
BibTeX
@article{MateoVargas2025,
author = {Mateo-Vargas, María Alejandra and Rodríguez-Pallares, Salud and Arca-Suárez, Jorge and López-Cerero, Lorena and Rodríguez-Iglesias, Manuel and Galán-Sánchez, Fátima},
title = {Emergence of KPC-8-producing K. pneumoniae infection without prior exposure to ceftazidime/avibactam: the threat of de novo infections by ceftazidime/avibactam-resistant KPC variants},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01494-24}
}
EUVIMED